Lv11
34 积分 2023-03-06 加入
Treatment of NSCLC after chemoimmunotherapy - are we making headway?
4小时前
已完结
Final analysis results and patient-reported outcomes from DESTINY-Lung02—a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic non–small cell lung cancer
9天前
已完结
Efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy as 1st line treatment for patients with non-small cell lung cancer harboring HER2 mutations: Results from LC-SCRUM-Asia
21天前
已完结
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
1个月前
已完结
Ivonescimab in advanced NSCLC: is progression-free survival enough, or are overall survival data also needed?
1个月前
已完结
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
1个月前
已完结
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
2个月前
已完结
Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis
2个月前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
3个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
皖公网安备34019202002308
